BMO Capital Maintains Outperform on Regeneron Pharmaceuticals, Lowers Price Target to $730

Benzinga Newsdesk www.benzinga.com Negative 94.2%

Neg 94.2% Neu 0% Pos 0%

BMO Capital analyst Evan David Seigerman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and lowers the price target from $900 to $730.